PD-1 Inhibitors Maintenance for cHL Post-autoHCT

"The choice of drug and its dose for maintenance therapy is at the discretion of the study centre (e.g. nivolumab, pembrolizumab). Maintenance therapy should be initiated no later than 60 days after D0, exceptions may be made due to reasonable justification in consultation with the Study PI and will not be considered a protocol deviation.~Nivolumab maintenance therapy regimens:~* Nivolumab (40 mg, fixed dose) IV D1 of each 14-days cycle up to 12 cycles~* Nivolumab (3 mg/kg) IV D1 of each 14-days cycle up to 12 cycles~Pembrolizumab maintenance therapy regimen:~-Pembrolizumab (200 mg, fixed dose) IV D1 of each 21-days cycle up to 8 cycles"